Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A high-dose form of Novo Nordisk’s obesity drug Wegovy, together with lifestyle intervention, led to greater ...

which is currently the highest dose of the drug marketed under the Wegovy brand for obesity. Digging into the data, participants in the 1,407-patient trial started from a mean baseline body weight ...

WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to ... “Some folks have to skip a dose in their prescription so they can make a prescription ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Ozempic, Wegovy and Other Drugs Are Among 15 Selected ... “Some folks have to skip a dose in their prescription so they can make a prescription last longer.” That brings the total to 25 ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish ...